Back to top
more

CareDx (CDNA)

(Delayed Data from NSDQ)

$7.56 USD

7.56
553,740

-0.42 (-5.26%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $7.56 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?

by Zacks Equity Research

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

How CareDx (CDNA) Stock Stands Out in a Strong Industry

by Zacks Equity Research

CareDx (CDNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

CareDx (CDNA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Unlocking Q4 Potential of CareDx (CDNA): Exploring Wall Street Estimates for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

How Much Upside is Left in CareDx (CDNA)? Wall Street Analysts Think 26.72%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can CareDx (CDNA) Climb 29.79% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for CareDx (CDNA) points to a 29.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

CareDx (CDNA) Surges 16.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CareDx (CDNA) delivered earnings and revenue surprises of 57.14% and 24.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Viatris (VTRS) delivered earnings and revenue surprises of 5.63% and 0.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) Soars 20.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CareDx (CDNA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

CareDx (CDNA) delivered earnings and revenue surprises of -57.14% and 3.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Cano Health, Inc. (CANO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cano Health, Inc. (CANO) delivered earnings and revenue surprises of 14.29% and 3.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Elevance Health (ELV) Beats on Q1 Earnings, Hikes Profit View

by Zacks Equity Research

Elevance Health's (ELV) first-quarter results reflect growing premiums stemming from rate increases.

CareDx (CDNA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

CareDx (CDNA) delivered earnings and revenue surprises of -16.67% and 0.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: CareDx (CDNA) Q4 Earnings Expected to Decline

by Zacks Equity Research

CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

UnitedHealth's (UNH) Optum to Boost Northern Light's Efficiency

by Zacks Equity Research

Per the deal, around 1,400 employees of Northern Light are likely to shift to UnitedHealth's (UNH) Optum this March.

HCA Healthcare (HCA) Unit in Talks to Buy Wise Health System

by Zacks Equity Research

HCA Healthcare's (HCA) deal with Wise Health System is expected to boost its footprint and market share in Texas.

Molina's (MOH) California Medicaid Revenues to Double in 2024

by Zacks Equity Research

Molina Healthcare (MOH) expects combined revenues from California, Nebraska, and Iowa in 2024 to reach $4.2 billion.

Why Hold Strategy is Apt for Centene (CNC) Stock Right Now

by Zacks Equity Research

Centene's (CNC) health benefits ratio is expected to improve in the coming days, signaling better operating efficiency.

Molina Healthcare (MOH) to Incur $200M Impairment Charge in Q4

by Zacks Equity Research

The reduction of Molina Healthcare's (MOH) real estate footprint is expected to result in a sizeable decline in leased real estate expense.

Here's Why CareDx (CDNA) Could be Great Choice for a Bottom Fisher

by Zacks Equity Research

CareDx (CDNA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

CareDx (CDNA) Loses 22.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

CareDx (CDNA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

CareDx (CDNA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

CareDx (CDNA) delivered earnings and revenue surprises of 57.14% and 2.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?